Arizona Opioid Essentials of MAT and Live Waiver Training 2018

Contact aschnock@azmed.org with any questions.  Hope to see you at upcoming events of the Arizona Psychiatric Society!

Arizona Psychiatric Society

<DIV CLASS="WordSection1">
<H2 CLASS="MsoNormal"><SPAN><IMG ALT="Opioid Use Disorder Essentials Information Banner with Logos" SRC="https://cdn.evbuc.com/eventlogos/39823372/banneropioidsessentials2018horizontal.jpg"></SPAN></H2>
<H2 CLASS="MsoNormal"><BR></H2>
<H2><SPAN>Session 1</SPAN><SPAN></SPAN></H2>
<H2 CLASS="MsoNormal">Saturday, January 20, 2018</H2>
<H2><BR></H2>
<H3 CLASS="MsoNormal">University of Arizona College of Medicine, Phoenix Campus</H3>
<H3 CLASS="MsoNormal"><SPAN>Health Sciences Education Building, Lecture Room B102</SPAN></H3>
<H3 CLASS="MsoNormal"><SPAN>435 North Fifth Street, Phoenix, Arizona</SPAN></H3>
<P CLASS="MsoNormal"><SPAN><BR></SPAN></P>
<H3 CLASS="MsoNormal"><SPAN>By Video to:</SPAN></H3>
<H3 CLASS="MsoNormal"><SPAN>University of Arizona College of Medicin, Tucson, Room 3230, 1501 North Campbell Avenue, Tucson; or</SPAN></H3>
<H3><SPAN>Flagstaff Medical Center, McGee Auditorium, 1200 North Beaver Avenue, Flagstaff</SPAN></H3>
<H4 CLASS="MsoNormal"> </H4>
</DIV>
<H3 CLASS="MsoNormal">Jointly Provided by American Psychiatric Association</H3>
<H3 CLASS="MsoNormal"><SPAN>and the Arizona Psychiatric Society</SPAN></H3>
<H3 CLASS="MsoNormal"><SPAN>in conjunction with</SPAN></H3>
<H3 CLASS="MsoNormal"><SPAN>Arizona Society of Addiction Medicine</SPAN></H3>
<P CLASS="MsoNormal"><SPAN> </SPAN></P>
<P CLASS="MsoNormal"><SPAN>Additional funding provided by the Arizona Psychiatric Society through an expedited grant from the American Psychiatric Association and facilities use and audio-visual support from the Department of Psychiatry, University of Arizona College of Medicine, Phoenix</SPAN><SPAN> </SPAN><SPAN>and facilities use and audio-visual support for the Session 1 remote broadcast provided by Flagstaff Medical Center and the Department of Psychiatry, University of Arizona College of Medicine, Tucson. </SPAN></P>
<P CLASS="MsoNormal"><BR></P>
<H2 CLASS="MsoNormal"><SPAN>AGENDA</SPAN></H2>
<P CLASS="MsoNormal">Welcome and Introduction<BR>James B. McLoone, MD, DLFAPA,<BR>Professor and Chair of Department of Psychiatry, University of Arizona College of Medicine – Phoenix; and <BR>Monica G. Faria, MD, President, Arizona Society of Addiction Medicine (AzSAM), and Conference Moderator<BR>7:50 to 8:00 am </P>
<P CLASS="MsoNormal">Current State of the Opioid Crisis in Arizona<BR>Shana Malone, MS<BR>Clinical Initiatives Project Manager, Arizona Healthcare Cost Containment System (AHCCCS) – Office of the Director<BR>8:00 to 9:00 am</P>
<P CLASS="MsoNormal">Opioid Crisis:  Identifying My Role as a Community Provider<BR>Simon Olstein, MD, FASAM<BR>Medical Director, Scottsdale Treatment, Inc. and Secretary of the Board of Directors, AzSAM<BR>9:00 to 10:00 am</P>
<P><I>Morning Break</I><BR>10:00 to 10:15 am<BR></P>
<P CLASS="MsoNormal">Opioids in Arizona – Approaches to Treatment<BR>Leonard F. Ditmanson, MD, FACP<BR>Medical Director, 5th Street Clinic, MAT Medical Director, ConnectionsAZ, Tucson, Arizona<BR>10:15 to 11:15 am</P>
<P CLASS="MsoNormal">Panel: Interdisciplinary Issues in Coordination of and Transitioning Levels of Care (Case Study with Perinatal Considerations (see below))</P>
<P CLASS="MsoNormal">Panel Members:</P>
<P CLASS="MsoNormal">Monica G. Faria, MD, Facilitator; <BR>Michael Dekker, DO, Addiction Psychiatrist; <BR>Christopher Luke Peterson, DO, Family Medicine, Banner Health; <BR>Maria Manriquez, MD, FACOG, Interim Associate Dean, Clinical Curriculum Professor, Department of Obstetrics and Gynecology Director, Pathway Scholars Program, University of Arizona College of Medicine, Phoenix; <BR>Elena Volfson, MD, Addiction Psychiatrist, Mayo Clinic Arizona; and<BR>Case Study Developed by:<BR>Edwin Kim, MD, Psychiatric Resident, Maricopa Integrated Health System</P>
<P CLASS="MsoNormal">11:15 am to 12:15 pm</P>
<P CLASS="MsoNormal">Thank you and Conclusion Session 1<BR>Aaron Wilson, MD, President, Arizona Psychiatric Society<BR>12:15 pm</P>
<P CLASS="MsoNormal"><STRONG>Networking Box Lunch</STRONG><BR><STRONG><EM>Advance Registration Required</EM></STRONG><BR>12:15 to 1:00 pm</P>
<P><STRONG>Session 2:  Live Waiver Training</STRONG><BR><STRONG>(Separately Accredited) (See Live Waiver Training Document for Complete Information)</STRONG><BR>Live Waiver Training<BR></P>
<P>Carlos Carrera MD, Anthony Dekker DO, Monica Faria MD, <BR>Anita Karnik MD, Show Lin MD, Luke Peterson DO<BR></P>
<P>1:00 to 5:15 pm<BR></P>
<P CLASS="MsoNormal"><STRONG>CASE STUDY FOR PANEL DISCUSSION</STRONG></P>
<P><I>Prepared by Edwin Kim, MD, PGY-4, Maricopa Integrated Health System, Inc.</I></P>
<P> A 33 year-old Caucasian G2P0010 female with opioid use disorder and history of peripartum depression presents to your (Primary Care Practice) clinic motivated to seek treatment for ongoing oxycodone and occasional heroin abuse. She denies childhood illness and chronic medical illness.  She did have miscarriage of her first pregnancy at age 19.  She denies medical illness or surgical history.  She did experience depression for over one year after her miscarriage.  She experienced some relief from sertraline (unknown dosage) which was prescribed after her depression progressed to strong thoughts of not finding life worth living.  She denies suicide attempt, attempt to self-harm and psychiatric hospitalization.  While pursuing her associates degree, she worked several side jobs before becoming a legal assistant.  During that time, she suffered a back injury which she "self-medicated" with marijuana. She possessed a medical marijuana card which she ultimately gave up after trying her boyfriend's opioid pain medication, oxycodone.  She feels the opioids also help her feel less depressed.  Today, she expresses her desire to have a safe pregnancy but is worried about possibly losing custody of her child and is willing to seek treatment as long as she can maintain custody.  Her boyfriend, who chronically uses opioid pain medication, has not been supportive of her current pregnancy.  She has minimal support as her family and relatives live primarily out of state. She denies alcohol use since age 25.  She quit smoking cigarettes as soon as she discovered she was pregnant.  Her concerns today include maintaining her pregnancy, maintaining her own health, and a fear of her depression returning.</P>
<H2>SESSION 1:  4.0 HOURS</H2>
<H2 CLASS="MsoNormal">GENERAL LEARNING OBJECTIVES</H2>
<P CLASS="MsoNormal"> At the conclusion, the attendee should be able to:</P>
<P CLASS="MsoNormal"> 1.         Discuss current epidemiological data reflecting the extent of the Opioid Use Crisis in AZ.</P>
<P CLASS="MsoNormal"><SPAN>2.         Recognize factors relating to diagnosis, referral to treatment, and management of Opioid Use Disorder as a chronic medical illness. </SPAN></P>
<P CLASS="MsoNormal">3.            Identify treatment guidelines for Opioid Use Disorder, including Medication Assisted Treatment and psychosocial components. </P>
<P CLASS="MsoNormal">4.            Describe clinically appropriate settings for buprenorphine induction.</P>
<P CLASS="MsoNormal"><SPAN>5.         Employ best courses of treatment, resources, or referral of care in common scenarios requiring multidisciplinary collaboration, including acute pain management for patients on medication assisted treatment of Opioid Use Disorder.  </SPAN></P>
<H3 CLASS="MsoNormal">ACCREDITATION</H3>
<P CLASS="MsoNormal">This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American Psychiatric Association (APA) and the Arizona Psychiatric Society.  The APA is accredited by the ACCME to provide continuing medical education for physicians.</P>
<H3 CLASS="MsoNormal">DESIGNATION</H3>
<P CLASS="MsoNormal">The APA designates this live activity for a maximum of <I>4.0</I> <I>AMA PRA Category 1 Credit™</I>.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.</P>
<H3 CLASS="MsoNormal">TARGET AUDIENCE</H3>
<P CLASS="MsoNormal">This educational activity is intended for psychiatrists and primary care and family care physicians.  All mental health professionals and general health professionals are welcome, including students and residents.</P>
<H2 CLASS="MsoNormal"><IMG ALT="Live Waiver Training AOAAM and PCSS-MAT" SRC="https://cdn.evbuc.com/eventlogos/39823372/apsazsamlivewaivertrainingimagew2logos.png"></H2>
<H2 CLASS="WordSection1">PCSS-MAT Live Waiver Training</H2>
<H2 CLASS="WordSection1"><SPAN>Session 2</SPAN></H2>
<H2 CLASS="WordSection1"><SPAN></SPAN>Saturday, January 20, 2018</H2>
<H2 CLASS="WordSection1">1:00 to 5:15 pm</H2>
<P CLASS="MsoNormal">Faculty:  <I> </I><EM>Carlos Carrera MD, Anthony Dekker DO, Monica Faria MD, Anita Karnik MD, Show Lin MD, Luke Peterson DO</EM></P>
<H3 CLASS="MsoNormal">SESSION 2:  4.25 HOURS</H3>
<UL>
<LI>The waiver eligibility training is available for physicians interested in seeking their waiver to prescribe buprenorphine in the treatment of opioid use disorders. In order to be eligible for the waiver to prescribe, providers are required to take 8-hours of training.</LI>
<LI>PCSS-MAT uses a Half-and-Half format in which 4.25-hours are attended face-to-face with an instructor and is combined with an “on your own” computer-based self-study consisting of 5 modules and a 24-question exam (3.75-hours). The combined face-to-face training and the online computer-study/exam provides the required 8-hours needed to obtain the waiver to prescribe buprenorphine in the office-based treatment of opioid use disorders. The link to access part 2 will be emailed to all participants who complete the 4.25-hour session in its entirety. It is mandatory that all participants sign in at the beginning of the training and again at the end. The AOAAM cannot verify your attendance unless both signatures are confirmed on the roster. Participants are required to complete part 2 within 30 days of receiving the link. </LI>
<LI CLASS="MsoNormal"><SPAN>Following the 8-hour completion, physicians who have successfully completed the course may apply to the Substance Abuse and Mental Health Services Administration (SAMHSA) to obtain the waiver. You will receive an email with directions on how to receive your certificate of completion and apply for the waiver.</SPAN></LI>
<LI CLASS="MsoNormalCxSpMiddle"><SPAN>Residents may take the 8-hour course and apply for their waiver once they receive their medical degree and their own DEA #.</SPAN></LI>
<LI CLASS="MsoNormalCxSpMiddle"><SPAN>Physician Assistants and Nurse Practitioners are also eligible for the waiver but only after 24-hours of required training have been completed. PAs and NPs are encouraged to participate in this 8-hour training, along with an additional 16-hours of training. The 16-hours can be accessed here:<BR> </SPAN><A HREF="http://pcssmat.org/education-training/mat-waiver-training/%20" TARGET="_blank" DATA-MSYS-CLICKTRACK="0" REL="nofollow noopener noreferrer"><SPAN>http://pcssmat.org/education-training/mat-waiver-training/</SPAN> </A></LI>
</UL>
<P CLASS="MsoNormalCxSpMiddle">This course has been reviewed and is acceptable for 4.25 credits of AOA Category 1A by the AOA CCMEthrough the AOAAM.  <STRONG><SPAN>It has also been reviewed and is acceptable for 4.25 Prescribed credit(s) by the American Academy of Family Physicians.</SPAN></STRONG><STRONG><SPAN></SPAN></STRONG></P>
<P CLASS="MsoNormalCxSpMiddle"><STRONG><I><SPAN>Physicians should claim only the credit commensurate with the extent of their participation in the activity. </SPAN></I></STRONG><I> </I><SPAN></SPAN></P>
<H3 CLASS="MsoNormal">TARGET AUDIENCE</H3>
<P CLASS="MsoNormal">This eligibility training is available for physicians interested in seeking their waiver to prescribe buprenorphine in the treatment of opioid use disorders.  In order to be eligible for the waiver to prescribe, providers are required to take 8-hours of training.  PCSS-MAT uses a Half-and-Half format in which 4.25-hours are attended face-to-face with an instructor and is combined with an “on your own” computer-based self-study consisting of 5 modules and a 24-question exam (3.75-hours). The combined face-to-face training and the online computer-study/exam provides the required 8-hours needed to obtain the waiver to prescribe buprenorphine in the office-based treatment of opioid use disorders. The link to access part 2 will be emailed to all participants who complete the 4.25-hour session in its entirety. It is mandatory that all participants sign in at the beginning of the training and again at the end. The AOAAM cannot verify your attendance unless both signatures are confirmed on the roster. Participants are required to complete part 2 within 30 days of receiving the link. </P>
<P CLASS="MsoNormal">Following the 8-hour completion, physicians who have successfully completed the course may apply to the Substance Abuse and Mental Health Services Administration (SAMHSA) to obtain the waiver. You will receive an email with directions on how to receive your certificate of completion and apply for the waiver.</P>
<P CLASS="MsoNormal">Residents may take the 8-hour course and apply for their waiver once they receive their medical degree and their own DEA #.</P>
<P CLASS="MsoNormal">Physician Assistants and Nurse Practitioners are also eligible for the waiver but only after 24-hours of required training have been completed. PAs and NPs are encouraged to participate in this 8-hour training, along with an additional 16-hours of training. The 16-hours can be accessed here:</P>
<P CLASS="MsoNormal"><A HREF="http://pcssmat.org/education-training/mat-waiver-training/" TARGET="_blank" DATA-MSYS-CLICKTRACK="0" REL="nofollow noopener noreferrer">http://pcssmat.org/education-training/mat-waiver-training/</A></P>
<P CLASS="MsoNormal"><I>Funding for this initiative was made possible (in part) by Providers’ Clinical Support System for Medication Assisted Treatment (1U79TI026556) from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.</I><I> </I></P>
<H3 CLASS="MsoNormal">Please note the Live Waiver Training (Session 2 alone) is free.  If you wish to register for Session 2 ONLY, please select the registration ticket for that option and then disclosure your role as a provider later in that same registration.    </H3>
<P CLASS="MsoNormal">Additional funding provided by the Arizona Psychiatric Society through an expedited grant from the American Psychiatric Association and facilities use and audio-visual support from the Department of Psychiatry, University of Arizona College of Medicine, Phoenix and facilities use and audio-visual support for the remote broadcast provided by Flagstaff Medical Center and the Department of Psychiatry, University of Arizona College of Medicine, Tucson. </P>
<P CLASS="MsoNormal"> </P>
<P><BR></P>
<P CLASS="MsoNormal"><BR><BR></P>

Lecture Room B102, Health Sciences Education Building

Thank you for your interest in the Opioid Use Disorders Essentials and Live Waiver Training event.  Walk-in registrations will be accepted on the date of the event beginning at 7:30 a.m.  If you would like information on future events, please contact teri@azmed.org, 602-316-3241.

Ticket sales have ended

Arizona Opioid Essentials of MAT and Live Waiver Training 2018

More events from Arizona Psychiatric Society

Discover more events from Arizona Psychiatric Society, from Health to other experiences you might love.

Ticket sales have ended

Arizona Opioid Essentials of MAT and Live Waiver Training 2018

More events from Arizona Psychiatric Society

Discover more events from Arizona Psychiatric Society, from Health to other experiences you might love.

You might also like...

Browse more events with different dates, prices, and formats to find your next great experience.